Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-0e4b0f32f27cd3409c6b65f9b73ff49f",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-0e4b0f32f27cd3409c6b65f9b73ff49f",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-0e4b0f32f27cd3409c6b65f9b73ff49f",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-0e4b0f32f27cd3409c6b65f9b73ff49f\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-0e4b0f32f27cd3409c6b65f9b73ff49f</b></p><a name=\"composition-en-0e4b0f32f27cd3409c6b65f9b73ff49f\"> </a><a name=\"hccomposition-en-0e4b0f32f27cd3409c6b65f9b73ff49f\"> </a><a name=\"composition-en-0e4b0f32f27cd3409c6b65f9b73ff49f-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1752/001 – 1 vial, 1 vial adaptor, 1 pre-filled syringe, 1 needle</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - abrysvo</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/23/1752/001 – 1 vial, 1 vial adaptor, 1 pre-filled syringe, 1 needle"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp0e4b0f32f27cd3409c6b65f9b73ff49f"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - abrysvo",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Abrysvo is and what it is used for</li><li>What you need to know before you receive Abrysvo</li><li>How Abrysvo is given</li><li>Possible side effects</li><li>How to store Abrysvo</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What abrysvo is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What abrysvo is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Abrysvo is a vaccine to prevent lung (respiratory tract) disease caused by a virus called respiratory syncytial virus (RSV). Abrysvo is given to:</p><ul><li>pregnant individuals to protect their infants from birth through 6 months of age or</li><li>individuals 60 years of age and older.</li></ul><p>RSV is a common virus which, in most cases, causes mild, cold-like symptoms such as a sore throat, cough or a blocked nose. However, in young infants RSV can cause serious lung problems. In older adults and people with chronic medical conditions, RSV can worsen illnesses such as chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF). RSV can lead to hospitalisation in severe cases and in some cases it can be fatal.</p><p>How Abrysvo works This vaccine helps the immune system (the body s natural defences) to make antibodies (substances in the blood that help the body fight infections) which protect against lung disease caused by RSV. In pregnant individuals who are vaccinated between weeks 24 and 36 of pregnancy, these antibodies are passed to the infant through the placenta before birth which protects infants when they are at most risk from RSV.</p></div>"
}
},
{
"title" : "2. What you need to know before you take abrysvo",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take abrysvo"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Abrysvo should not be given</p><ul><li>if you are allergic to the active substances or any of the other ingredients of this vaccine (listed in section 6).</li></ul><p>Warnings and precautions Talk to your doctor, pharmacist or nurse before you are given this vaccine</p><ul><li>if you have ever had a severe allergic reaction or breathing problems after you received any other vaccine injection or after you were given Abrysvo in the past.</li><li>if you are feeling nervous about getting the vaccine or have ever fainted after any injection. Fainting can happen before or after any injection</li><li>if you have an infection with a high fever. If this is the case, then vaccination will be postponed. There is no need to delay vaccination for a minor infection, such as a cold, but talk to your doctor first.</li><li>if you have a bleeding problem or bruise easily.</li><li>if you have a weakened immune system which may prevent you from getting the full benefit from Abrysvo.</li><li>if you are less than 24 weeks pregnant.</li></ul><p>If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given Abrysvo.</p><p>As with any vaccine, Abrysvo may not fully protect all those who receive it.</p><p>Children and adolescents Abrysvo is not recommended in children and young people below 18 years of age except during pregnancy (see Pregnancy section below).</p><p>Other medicines and Abrysvo Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines or have recently received any other vaccine.</p><p>Abrysvo may be given at the same time as a flu vaccine. A gap of at least two weeks is recommended between administration of Abrysvo and administration of a vaccine against tetanus, diphtheria and acellular pertussis (whooping cough).</p><p>Pregnancy and breast-feeding Pregnant individuals can be given this vaccine in the late second or third trimester (weeks 24 to 36). Talk to your doctor or nurse for advice before getting this vaccine if you are breast-feeding.</p><p>Driving and using machines Abrysvo is unlikely to affect your ability to drive or use machines.</p><p>Abrysvo contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free .</p></div>"
}
},
{
"title" : "3. How to take abrysvo",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take abrysvo"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>You will be given one injection of 0.5 mL into a muscle of your upper arm.</p><p>If you have any questions on the use of Abrysvo, ask your doctor, pharmacist or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all vaccines, this vaccine can cause side effects, although not everybody gets them.</p><p>Serious side effects</p><p>Rare (may affect up to 1 in 1 000 people)</p><ul><li>Guillain-Barr syndrome (a neurological disorder that usually starts with pins and needles and weakness of the limbs and may progress up to paralysis of part or all of the body).</li></ul><p>Very rare (may affect up to 1 in 10 000 people)</p><ul><li>allergic reactions - signs of an allergic reaction include swelling of the face, lips, tongue or throat, hives, difficulty breathing or swallowing and dizziness. See also section 2. Tell your doctor immediately if you notice signs of these serious side effects.</li></ul><p>The following side effects were reported in pregnant individuals</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>pain where the injection is given</li><li>headache</li><li>muscle pain (myalgia).</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>redness where the injection is given</li><li>swelling where the injection is given.</li></ul><p>No side effects were reported in infants born to vaccinated mothers.</p><p>The following side effects were reported in individuals 60 years of age and older</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>pain where the injection is given</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>redness where the injection is given</li><li>swelling where the injection is given.</li></ul><p>Rare (may affect up to 1 in 1 000 people)</p><ul><li>Guillain-Barr syndrome (see Serious side effects, above).</li></ul><p>Very rare (may affect up to 1 in 10 000 people)</p><ul><li>allergic reactions (see Serious side effects, above).</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store abrysvo",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store abrysvo"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2 C - 8 C).</p><p>Do not freeze. Discard if the carton has been frozen.</p><p>After reconstitution Abrysvo should be administered immediately or within 4 hours if stored between 15 C and 30 C. Do not freeze.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Abrysvo contains</p><p>The active substances are: RSV subgroup A stabilised prefusion F antigen1,2 60 micrograms RSV subgroup B stabilised prefusion F antigen1,2 60 micrograms (RSV antigens) 1glycoprotein F stabilised in the prefusion conformation 2produced in Chinese Hamster Ovary cells by recombinant DNA technology.</p><p>The other ingredients are: Powder</p><ul><li>trometamol</li><li>trometamol hydrochloride</li><li>sucrose</li><li>mannitol</li><li>polysorbate * sodium chloride</li><li>hydrochloric acid Solvent</li><li>water for injections</li></ul><p>What Abrysvo looks like and contents of the pack</p><p>Abrysvo is provided as</p><ul><li>a white powder in a glass vial</li><li>a solvent in a pre-filled syringe to dissolve the powder After dissolving the powder in the solvent, the solution is clear and colourless. Abrysvo is available in</li><li>a carton containing 1 vial of powder, 1 pre-filled syringe of solvent, 1 vial adaptor, with 1 needle or without needles.</li><li>a carton containing 5 vials of powder, 5 pre-filled syringes of solvent, 5 vial adaptors, with 5 needles or without needles.</li><li>a carton containing 10 vials of powder, 10 pre-filled syringes of solvent, 10 vial adaptors, with 10 needles or without needles.</li></ul><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder Pfizer Europe MA EEIG Boulevard de la Plaine 1050 Bruxelles<br/>Belgium</p><p>Manufacturer Pfizer Manufacturing Belgium NV Rijksweg 2870 Puurs-Sint-Amands Belgium</p><p>Pfizer Ireland Pharmaceuticals Grange Castle Business Park Clondalkin, Dublin Ireland</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Luxembourg/Luxemburg Pfizer NV/SA T l/Tel: + 32 (0)2 554 62 Latvija Pfizer Luxembourg SARL fili le Latvij<br/>Tel.: + 371 670 35<br/>,<br/>Te : +359 2 970 4Magyarorsz g Pfizer Kft Tel: + 36 1 488 37 esk republika Pfizer, spol. s r.o.<br/>Tel: +420 283 004 Malta Vivian Corporation Ltd. Tel: + 356 21344Danmark Pfizer ApS Tlf: + 45 44 20 11 Nederland Pfizer bv Tel: +31 (0)800 63 34 Deutschland PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51Norge Pfizer AS Tlf: +47 67 52 61 Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7 sterreich Pfizer Corporation Austria Ges.m.b.H Tel: +43 (0)1 521 15-0</p><p>Pfizer A.E. .: +30 210 6785Polska Pfizer Polska Sp. z o.o. Tel.: +48 22 335 61 Espa a Pfizer, S.L. T lf: +34 91 490 99 Portugal Laborat rios Pfizer, Lda. Tel: +351 21 423 5France Pfizer T l +33 (0)1 58 07 34 Rom nia Pfizer Romania S.R.L Tel: +40 (0) 21 207 28 Hrvatska Pfizer Croatia d.o.o. Tel: + 385 1 3908 Slovenija Pfizer Luxembourg SARL Pfizer, podru nica za svetovanje s podro ja farmacevtske dejavnosti, Ljubljana Tel.: +386 (0)1 52 11 Ireland Pfizer Healthcare Ireland Tel: +1800 633 363 (toll free) Tel: +44 (0)1304 616Slovensk republika Pfizer Luxembourg SARL, organiza n zlo ka Tel: + 421 2 3355 5 sland Icepharma hf. Simi: + 354 540 8Suomi/Finland Pfizer Oy Puh/Tel: +358 (0)9 430 Italia Pfizer S.r.l.<br/>Tel: +39 06 33 18 Sverige Pfizer AB Tel: +46 (0)8 550 520 K<br/>Pfizer . . (Cyprus Branch) T : +357 22817United Kingdom (Northern Ireland) Pfizer Limited Tel: + 44 (0) 1304 616This leaflet was last revised in</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp0e4b0f32f27cd3409c6b65f9b73ff49f",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp0e4b0f32f27cd3409c6b65f9b73ff49f",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp0e4b0f32f27cd3409c6b65f9b73ff49f\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp0e4b0f32f27cd3409c6b65f9b73ff49f</b></p><a name=\"mp0e4b0f32f27cd3409c6b65f9b73ff49f\"> </a><a name=\"hcmp0e4b0f32f27cd3409c6b65f9b73ff49f\"> </a><a name=\"mp0e4b0f32f27cd3409c6b65f9b73ff49f-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1752/001 – 1 vial, 1 vial adaptor, 1 pre-filled syringe, 1 needle</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Abrysvo powder and solvent for solution for injection</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/23/1752/001 – 1 vial, 1 vial adaptor, 1 pre-filled syringe, 1 needle"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Abrysvo powder and solvent for solution for injection",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
